Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Topical Minocycline Foam FXFM244

Phase 1Small molecule

VVyne Therapeutics Inc.

1

Indications

4

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Confluent and Reticulated Papillomatosis (CARP)Not yet recruiting

Confluent and Reticulated Papillomatosis (CARP)Phase 1

Not yet recruiting

Timeline

Expected Milestones

Q1 2028

Phase 1Not yet recruiting

Confluent and Reticulated Papillomatosis (CARP)

NCT07462702

Clinical

Trials by Indication[1]

Acne Vulgaris1 trial

Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris Patients

Completed·VVyne Therapeutics Inc.·Phase 2·NCT01362010·150 enrolled

Impetigo1 trial

Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients

Completed·VVyne Therapeutics Inc.·Phase 2·NCT01171326·32 enrolled

Rosacea1 trial

Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients

Terminated·VVyne Therapeutics Inc.·Phase 2·NCT01134991·21 enrolled

Confluent and Reticulated Papillomatosis (CARP)1 trial

Topical Minocycline Foam for Treatment of Confluent and Reticulated Papillomatosis (CARP)

Not yet recruiting·MMedical University of South Carolina·Phase 1·NCT07462702·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Topical Minocycline Foam FXFM244. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Topical Minocycline Foam FXFM244 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Topical Minocycline Foam FXFM244. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vyne Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: VVyne Therapeutics Inc.

Related News